Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 17
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
The Role of Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Diagnostic
Active
18 and over
Other
FLT-PET CRC-LM
NCT00145665
2.
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
OSI3926g
ML20773, NCT00453362
3.
Assessment of 18FLT PET-CT for Volume Definition of High-Grade Gliomas (GLIO-TEP)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Diagnostic
Active
Over 18
Other
9420-04
2004-033, NCT00624728
Last Modified:
8/23/2008
 
First Published:
11/14/2007
4.
Phase II Study of the Effect of Zoledronic Acid on Standardized Uptake Value By Positron Emission Tomography in Patients With Advanced Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Diagnostic
Active
18 and over
NCI
WSU-2006-136
2006-136, NCT00559897
Last Modified:
8/29/2008
 
First Published:
11/29/2007
5.
Phase II Study of 3'-deoxy-3'-18F Fluorothymidine Positron Emission Tomography/CT Scanning in Patients Undergoing Treatment for Stage IIIA, IIIB, or IIIC Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Diagnostic, Treatment
Active
18 and over
NCI
MCV-HM11081
HM11081, 8029, NCT00566293
6.
Erlotinib and Sequential PET in Advanced Non Small Cell Lung Cancer (NSCLC)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Diagnostic, Treatment
Active
18 and over
Other
2005-005393-73
06159, NCT00568841
7.
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Diagnostic
Active
18 and over
NCI, Other
200801758
1R21CA130281, NCT00721799
First Published:
9/19/2008
8.
Phase II Pilot Study of 3'-deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiotherapy in Patients With Advanced Squamous Cell Carcinoma of the Oropharynx, Larynx, or Hypopharynx
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Diagnostic, Treatment
Approved-not yet active
18 and over
NCI
MAYO-MC057M
MC057M, NCT00757549, MAYO-08-002166
9.
Validation of 18F-MISO-PET and 18F-FLT-PET
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Diagnostic, Treatment
Active
Over 18
Other
100
NCT00159978
Last Modified:
10/9/2007
 
First Published:
7/6/2007
10.
Phase I Study of Sunitinib Malate in Patients With Unresectable or Metastatic Clear Cell Renal Cell Carcinoma or Other Advanced Solid Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
WCCC-CO-06902
CO 06902, 7898, NCT00499135
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute